ID: ALA365894

Max Phase: Preclinical

Molecular Formula: C12H9Cl2N3O2

Molecular Weight: 298.13

Molecule Type: Small molecule

Representations

Canonical SMILES:  N/C(=N/O)c1ccc(Oc2c(Cl)cncc2Cl)cc1

Standard InChI:  InChI=1S/C12H9Cl2N3O2/c13-9-5-16-6-10(14)11(9)19-8-3-1-7(2-4-8)12(15)17-18/h1-6,18H,(H2,15,17)

Standard InChI Key:  GQLWJSLITHXMLU-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 298.13

Molecular Weight (Monoisotopic): 297.0072

AlogP: 3.28

#Rotatable Bonds: 3

Polar Surface Area: 80.73

Molecular Species: NEUTRAL

HBA: 4

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 5

HBD (Lipinski): 3

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 7.64

CX Basic pKa: 5.04

CX LogP: 2.38

CX LogD: 2.10

Aromatic Rings: 2

Heavy Atoms: 19

QED Weighted: 0.39

Np Likeness Score: -0.76

References

1. Rastelli G, Pacchioni S, Sirawaraporn W, Sirawaraporn R, Parenti MD, Ferrari AM..  (2003)  Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors.,  46  (14): [PMID:12825927] [10.1021/jm030781p]

2. Parenti MD, Pacchioni S, Ferrari AM, Rastelli G..  (2004)  Three-dimensional quantitative structure-activity relationship analysis of a set of Plasmodium falciparum dihydrofolate reductase inhibitors using a pharmacophore generation approach.,  47  (17): [PMID:15293997] [10.1021/jm040769c]

Source

Source(1):

• Scientific Literature